Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 16, 2023 06:17 ET | Source: Pharma Equity Group A/S

Pharma Equity Group’s datterselskab (Reponex Pharmaceuticals A/S) opnår de primære endpoints i selskabets kliniske fase 2 studie med lægemiddelkandidaten RNX-051.

16. november 2023 Selskabsmeddelelse nr. 45 Pharma Equity Group’s datterselskab (Reponex Pharmaceuticals A/S) opnår de primære endpoints i selskabets kliniske fase 2 studie med lægemiddelkandidaten...
November 16, 2023 06:17 ET | Source: Pharma Equity Group A/S

Pharma Equity Group’s subsidiary (Reponex Pharmaceuticals A/S) meets the primary endpoints in the phase-2 clinical trial of the drug candidate RNX-051.

16 November 2023 Company Announcement no. 45 Pharma Equity Group’s subsidiary (Reponex Pharmaceuticals A/S) meets the primary endpoints in the phase-2 clinical trial of the drug candidate RNX-051. ...
November 16, 2023 02:26 ET | Source: Pharma Equity Group A/S

Konsolideret delårsrapport 1. januar – 30. september 2023

Konsolideret delårsrapport 1. januar – 30. september 2023 16. november 2023 Selskabsmeddelelse nr. 44 Hovedpunkter (ni-måneders rapport afsluttet 30. september 2023) Bestyrelsen og direktionen i...
November 16, 2023 02:26 ET | Source: Pharma Equity Group A/S

Consolidated interim report 1 January – 30 September 2023

Consolidated interim report 1 January – 30 September 2023 16 November 2023 Company Announcement no. 44 Key points (nine-month report ended 30 September 2023) On 16 November 2023, the Board of...
November 02, 2023 10:14 ET | Source: Pharma Equity Group A/S

Forløb af ekstraordinær generalforsamling i Pharma Equity Group A/S

2. november 2023 Meddelelse nr. 43 Forløb af ekstraordinær generalforsamling i Pharma Equity Group A/S Pharma Equity Group A/S afholdte i dag ekstraordinær generalforsamling, hvor...
November 02, 2023 10:14 ET | Source: Pharma Equity Group A/S

Resolutions of the Extraordinary General Meeting of Pharma Equity Group A/S

2 November 2023 Announcement no. 43 Resolutions of the Extraordinary General Meeting of Pharma Equity Group A/S Pharma Equity Group A/S today held its Extraordinary General Meeting with...
October 31, 2023 08:18 ET | Source: Pharma Equity Group A/S

Pharma Equity Group’s datterselskab (Reponex Pharmaceuticals A/S) modtager EPO meddelelse om udstedelse af patenter på behandling med datterselskabets sårhelende lægemiddelkombination samt behandling mod Colorektal Cancer.

31. oktober 2023 Selskabsmeddelelse nr. 42 Pharma Equity Group’s datterselskab (Reponex Pharmaceuticals A/S) modtager European Patent Office (EPO) meddelelse om udstedelse af patent på behandling...
October 31, 2023 08:18 ET | Source: Pharma Equity Group A/S

Pharma Equity Group's subsidiary (Reponex Pharmaceuticals A/S) receives a notification from the EPO regarding the “Intention to Grant” for patents of the subsidiary's wound-healing drug combination and the treatment of colorectal cancer.

October 31, 2023 Company Announcement No. 42 Pharma Equity Group's subsidiary (Reponex Pharmaceuticals A/S) receives a notification from the European Patent Office (EPO) regarding the...
October 31, 2023 06:57 ET | Source: Pharma Equity Group A/S

Pharma Equity Group’s datterselskab (Reponex Pharmaceuticals A/S) har modtaget meddelelse om godkendelse af patent på behandling med datterselskabets sårhelende lægemiddelkombination.

31. oktober 2023 Selskabsmeddelelse nr. 41 Pharma Equity Group’s datterselskab (Reponex Pharmaceuticals A/S) har modtaget meddelelse om godkendelse af patent på behandling med datterselskabets...
October 31, 2023 06:57 ET | Source: Pharma Equity Group A/S

Pharma Equity Group’s subsidiary company (Reponex Pharmaceuticals A/S) have received grant of US Patent for a method of treatment on its topical wound-healing composition.

31 October 2023 Announcement no. 41 Pharma Equity Group’s subsidiary company (Reponex Pharmaceuticals A/S) have received grant of US Patent for a method of treatment on its topical wound-healing...